How to Administer Uzedy Subcutaneously in the Abdomen
Uzedy should be administered by a healthcare professional as a subcutaneous injection in the abdomen using proper injection technique, with the injection site rotated between the abdomen and upper arm as both sites provide equivalent pharmacokinetic profiles. 1
Administration Technique
Site Selection and Preparation
- The abdomen is an approved injection site that provides similar pharmacokinetic profiles compared to the upper arm, allowing these sites to be used interchangeably 1
- The abdomen offers a thicker subcutaneous layer and provides rapid absorption, making it a suitable primary injection site 2
Injection Procedure
According to the FDA label, Uzedy must be:
- Administered by a healthcare professional only - this is not for patient self-injection 1
- Given subcutaneously - do not administer by any other route 1
- Injected in either the abdomen or upper arm 1
Dosing Considerations
The specific dose depends on the patient's current oral risperidone regimen:
- For patients on 2 mg daily oral risperidone: 50 mg monthly or 100 mg every 2 months
- For patients on 3 mg daily: 75 mg monthly or 150 mg every 2 months
- For patients on 4 mg daily: 100 mg monthly or 200 mg every 2 months
- For patients on 5 mg daily: 125 mg monthly or 250 mg every 2 months 1
Key Clinical Points
Pharmacokinetic Profile
- Therapeutic concentrations are achieved within 6-24 hours after the first injection, eliminating the need for oral supplementation 1
- The abdomen and upper arm demonstrate bioequivalent pharmacokinetic profiles, with median time to maximum concentration (tmax) ranging from 8-14 days 1, 3
- Steady-state levels are reached within 2 months of initiation 1
Tolerability
Research indicates that injection site pain is generally mild and transient:
- Mean pain scores on visual analog scale were approximately 27 at 1 minute post-injection, decreasing to 3-7 within 30-60 minutes 4
- Injection site nodules occurred in approximately 7% of patients but were generally well-tolerated 5
Important Caveats
Critical prerequisite: Establish tolerability with oral risperidone prior to initiating Uzedy 1. This is a mandatory step to ensure the patient can tolerate the medication before committing to a long-acting formulation.
Site rotation: While both abdomen and upper arm are approved, alternating between sites may help minimize local injection site reactions, though this is not explicitly required by the label 1, 3.
Refer to full prescribing information for complete preparation and administration details, as the FDA label notes there are important preparation steps not fully detailed in the dosing section 1.